Monday, November 8, 2010

Payday Company Settles Claims for almost $20 Million

Payday Loans Neon SignImage by rinkjustice via FlickrAdvance America, the country’s largest payday lender, has agreed to pay $18.75 million to more than 140,000 North Carolina consumers under a proposed settlement agreement announced September 21 by the consumers’ attorneys. The settlement will resolve a 2004 class action lawsuit against Advance America that accused it of charging illegal fees and interest rates.



The company had already stopped lending in North Carolina as a result of an investigation action brought by the North Carolina Attorney General’s Office and the North Carolina Office of the Commissioner of Banks. Advance America affiliates that signed the agreement operated 118 branch offices throughout North Carolina.

“I have been closely monitoring a lot of the consumer protection litigation against payday lenders around the country,” said Public Justice Senior Attorney Paul Bland, one of the plaintiffs’ lawyers, “and as far as I am aware, this is by far the largest settlement that any class of consumers has won from any payday lender in the United States. It is the single biggest achievement on behalf of consumers against payday lenders that I have seen in any private lawsuit in the U.S.”

So-called “payday loans” are short-term loans or cash advances, usually for a period of 14 days, secured by a post-dated check for the full amount of the loan plus interest or other fees. Payday loans typically require triple digit interest rates. The class representatives in Kucan v. Advance America, the North Carolina suit, obtained loans from Advance America with annual percentage rates exceeding 450%. North Carolina law caps interest for that type of loan at 36%.

 "We are pleased that Advance America has agreed to compensate North Carolina consumers who have been adversely affected by those practices," said Carlene McNulty of the North Carolina Justice Center in Raleigh, one of the attorneys representing the plaintiffs. "It’s a model we encourage – to not only abandon bad practices but to try to make amends for them.”

Attorneys say class action lawsuits against unscrupulous payday lenders will continue. Consumer representatives congratulated Advance America for taking this big step to make things right with its customers, but also noted that several other North Carolina payday lenders are still using delay tactics and specious arguments about why their contracts immunize them from state law.
“There are still four major payday lenders in North Carolina who took tens of millions of dollars in illegal fees from consumers who continue to drag out consumer protection cases,” said Mal Maynard of the Financial Protection Law Center in Wilmington, N.C., another attorney for the plaintiffs. “We are happy that Advance America has done the responsible thing, but we are not going to let down for one moment in the other cases.” Maynard said the legal team will pursue litigation against the other payday lenders “until they do the right thing as well.”

Class action lawsuits to recover funds for illegally charged and overcharged borrowers are part of a one-two punch against illegal payday lending practices in the state. North Carolina Attorney General Roy Cooper has been active in pursuing payday lenders and forcing them to cease operations in North Carolina. The Attorney General’s Office previously reached an agreement with three other major payday lenders, Check Into Cash, Check N Go and First American Cash Advance, to stop making the illegal payday loans in the state.
Consumers who got a payday loan at Advance America or National Cash Advance in North Carolina on or after March 1, 2003, will receive payments as part of the proposed settlement. They will not need to file a claim to be able to participate in the settlement. If the settlement is approved, checks will be mailed to all class members who can be located, beginning in the first half of 2011.

In agreeing to pay consumer claims, Advance America has not admitted that it has violated any North Carolina law. Judge D. Jack Hooks, Jr. of New Hanover County Superior Court has been asked to approve the settlement.

Source: http://publicjustice.net/Newsroom/News/North-Carolina-Class-Action-against-Payday-Lender.aspx

Enhanced by Zemanta

November Reglan News (Florida- Jacksonville, Tallahassee, Gainesville)

The U.S. Solicitor General has asked the U.S. Supreme Court to reject an appeal by pharmaceutical companies in a generic Reglan lawsuit, in a case known as the Mensing decison.

The manufacturers of the generic Reglan, metoclopramide, are seeking a reversal of an appellate court decision that holds them liable for failing to warn patients about the risk of tardive dyskinesia, a rare movement disorder linked to the drug. The Supreme Court asked the U.S. Solicitor General for an opinion on the accountability of generic Reglan manufacturers.

The Solicitor General supported the appellate court ruling in an amicus brief that had been filed a week ago.  “The court of appeals correctly held that respondent’s failure-to-warn claims are not categorically preempted,” the brief said. “A generic manufacturer can (and indeed, must) inform the FDA of new information about the risks that may require a change in the labeling of its drug.”

Wednesday, October 20, 2010

Florida Avandia News

AvandiaImage by neofedex via Flickr
A good report from American Counsel on Science and Health:

As drugs continue to be taken for longer periods of time, unexpected complications may arise that were absent from short-term clinical trials. New York Times science journalist Gina Kolata reported on what happens when drugs cause problems they were originally developed to prevent, focusing on the risks associated with the now highly restricted diabetes drug Avandia, and bisphosphonates, a class of medicine used to treat osteoporosis. 

After post-market analysis revealed that Avandia is alleged to be associated with an increased risk of heart failure, the drug was temporarily removed from the market in Europe and then restricted by the FDA last month. 

Diabetic treatment is supposed to reduce the rate of diabetic complications including vascular disease, kidney disease and neuropathy — not merely control blood sugar. Studies that show Avandia may increase the risk of heart failure illustrate a case of when a drug does the opposite of what it’s supposed to.” 

Here is the link: http://www.acsh.org/factsfears/newsID.1961/news_detail.asp

In the Middle East, this news:
The UAE Ministry of Health has ordered all doctors and hospitals to suspend prescribing the diabetes drug Avandia.

According to a circular issued Sunday, health officials have decided to suspend all products containing Rosiglitazone over fears in the United States and Europe over its safety. Bahraini health officials have also banned drugs containing Rosiglitazone, like Avandaryl, Avandamet and Avandia, the Gulf Daily News reports.

Dr Ameen Al Amiri, CEO for medical practice and licensing at the ministry, was reported by the official news agency WAM as saying the drug control directorate had held extensive talks with Avandia’s manufacturers and local distributors.

http://www.arabianbusiness.com/avandia-diabetes-drug-be-banned-over-health-fears-351519.html


http://www.markzamora.com/AvandiaGA/index.html
Enhanced by Zemanta

Tuesday, October 12, 2010

FDA : Recent Recalls


Fda
The folks at the FDA have been busy the past several weeks. Here's a short list of recalls:

Amgen Initiates Voluntary Nationwide Recall of Certain Lots Of Epogen® And Procrit® (Epoetin Alfa):The product that is being recalled may contain extremely thin glass flakes (lamellae) that are barely visible in most cases. The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product. The products are indicated for the treatment of anemia related to HIV therapy, chronic renal failure, and chemotherapy. Link.

 

Pfizer Consumer Healthcare Issues Voluntary Recall of One Lot of ThermaCare HeatWraps Menstrual Product  The company said it is taking this precautionary step after finding a potential for a leak of the components contained in the wrap, which could cause skin injury such as irritation or burn. Link

 

Recall of AROM-X Capsules, AROM-X UTT Liquid, AROM-XL Liquid, 4-AD Capsules and Decavol Capsules Marketed as a Dietary Supplements Containing ATD: FDA's states that the ingresidnets 1,4,6 etioallocholan-dione do not meet the definition of a dietary ingredient and therefore the product is in violation of provisions of the Food, Drug and Cosmetic Act.

 

Recall of Reversitol a Product Marketed as a Dietary Supplement Containing ATD: FDA has requested that iForce Nutrition inform consumers that adverse events associated with the use of aromatase inhibitors could include the following: decreased rate of bone maturation and growth, decreased sperm production, infertility, aggressive behavior, adrenal insufficiency, kidney failure, and liver dysfunction. Consumers with liver, kidney, adrenal, or prostate abnormalities are at higher risk for developing adverse events. iForce Nutrition has not received any adverse event reports nor are they aware of any adverse events associated with the use of these products. Link.

Monday, October 11, 2010

Florida: Meridia Recalled

From the FDA:

AUDIENCE: Primary Care, Consumers

ISSUE: Abbott Laboratories and FDA notified healthcare professionals and patients about the voluntary withdrawal of Meridia (sibutramine), an obesity drug, from the U.S. market because of clinical trial data indicating an increased risk of heart attack and stroke.

BACKGROUND: Meridia was approved November 1997 for weight loss and maintenance of weight loss in obese people, as well as in certain overweight people with other risks for heart disease. The approval was based on clinical data showing that more people receiving sibutramine lost at least 5 percent of their body weight than people on placebo who relied on diet and exercise alone. FDA has now requested market withdrawal after reviewing data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT). SCOUT is part of a postmarket requirement to look at cardiovascular safety of sibutramine after the European approval of the drug. The trial demonstrated a 16 percent increase in the risk of serious heart events, including non-fatal heart attack, non-fatal stroke, the need to be resuscitated once the heart stopped, and death, in a group of patients given sibutramine compared with another given placebo. There was a small difference in weight loss between the placebo group and the group that received sibutramine.

RECOMMENDATION: Physicians are advised to stop prescribing Meridia to their patients, and patients should stop taking this medication. Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs.

Talk to us at 404-451-7781

Wednesday, September 8, 2010

FL Courts: Recent Decision Including Proof of Medical Expenses

Date: 08-26-2010
Case Style: Giani Fasani v. Christian Kowalski
Case Number: 3D09-2299 & 3D09-2350
Judge: Lagoa
Court: Florida Court of Appeal, Third District on appeal from the Circuit Court for Miami-Dade County

Description: The appellants, Giani Fasani (“Fasani”) and 420 Lincoln Road Associates, Ltd. (“Lincoln”) (collectively “appellants”), appeal from a final judgment entered in favor of the appellee, Christian Kowalski (“Kowalski”). The appellants raise two issues. First, they argue that counsel for Kowalski engaged in improper arguments such that the trial court abused its discretion in denying their motion for a new trial. Second, they assert that the trial court erred in failing to grant their motion for directed verdict on Kowalski’s claim for future medical expenses. We agree with the appellants on both points.

I. FACTUAL AND PROCEDURAL HISTORY

Kowalski entered an elevator at his workplace, which was located at 420 Lincoln Road, a building owned by Lincoln. The elevator contained granite-tiled walls installed by Fasani. While Kowalski and his co-worker, Harold Salazar, were riding in the elevator, one of the granite tiles separated from the wall and struck Kowalski on his head. Kowalski subsequently filed an amended complaint against Lincoln, and Lincoln, in turn, filed a third party complaint against Fasani.

Prior to trial commencing, the appellants admitted liability. The case then proceeded to a four-day trial on the issues of proximate cause and compensatory damages only. Before closing arguments, the appellants moved for directed verdict as to Kowalski’s future medical expenses claim, arguing that Kowalski did not present evidence that was sufficient to justify an award of future medical expenses. This motion was denied.

The jury ultimately awarded Kowalski $413,434.00 in damages.

Specifically, the jury awarded $13,434.00 for past medical expenses and $120,000.00 for future medical expenses. Kowalski was awarded no lost wages, and was awarded $30,000.00 for loss of future earning capacity. Lastly, he was awarded $100,000.00 for pain and suffering in the past, and $150,000.00 for future pain and suffering. After the trial court entered final judgment, the appellants each filed motions for a new trial and/or remittitur, arguing that improper comments and arguments made by Kowalski’s counsel denied them a fair trial, and that there was no evidence to support the $120,000 award for future medical expenses. The trial court denied the motions, and this appeal ensued. Counsel’s Improper Opening and Closing Statements During Trial During opening statements, Kowalski’s counsel stated, over objection: “This is a case about a company, 420 Lincoln Road that wanted to make a couple of extra dollars.” The appellants claim that during closing argument, Kowalski’s counsel’s “theme” was that the appellants simply wanted Kowalski to go away rather than for them to have done the “right” thing. Kowalski’s counsel stated:

So what did defense counsel do when he took the stand?

They ridiculed her [Plaintiff’s mother], they made fun of her for giving him aspirin. Well, I would tell you this. If they did the right thing, why didn’t they give him an aspirin. Why didn’t they send him to a doctor instead of just kicking him out on the street like a dog and telling him we’re giving you nothing. . . . [Objection raised and overruled]. They did nothing for him. They told him, we’re wrong, we shouldn’t have done it, it’s our fault, we did the right thing, we’re giving you nothing. Well, is that really doing the right thing.

* * * *

Is that doing the right thing? Giving him nothing and telling him to go away? [Objection raised and overruled].

Kowalski’s counsel then attributed the unsafe condition of the elevator to the appellants’ “corporate arrogance and corporate greed.” He stated: Members of the jury, what you’ve heard is that this is nothing more than corporate arrogance and corporate greed. They wanted a pretty elevator and they didn’t care who got hurt or how bad it was. And when someone got hurt, they said, you know what, yeah, we made a mistake but we’re not giving you anything. [Objection raised and overruled].

Kowalski’s counsel continued:

Now, members of the jury, you’ve got to understand that the brain is what separates people from animals. It’s what makes us human. I mean I’m sure you’ve all heard the expression, well, he may be old but he still has his mind or memories are what make us who we are. If that was a Picasso painting that was in the elevator and it got ripped, no one would argue with paying $80 million to replace it. Why is it any different when it’s a man’s brain? Why is it any different when it’s a man’s brain who’s had an injury the equivalent to a stroke who’s had post-concussion syndrome, posttraumatic stress disorder.

You heard the kind of symptoms he had. Trouble remembering, trouble concentrating, trouble thinking.

He has nightmares, he has migraines. Who would like to go through - - that’s the equivalent of having somebody hit you in the head with a baseball bat. Ask a reasonable person, look, how much money would you take for me to hit you in the head with a baseball bat as hard as I can? He didn’t get that choice. Nobody asked him what’s it worth. They just did it. And afterwards we’re giving you nothing. How is that doing the right thing? This is nothing more than corporate arrogance.

* * * *

Members of the jury, you’re the ones that have the power so that they can’t get away with this. It’s up to you. And when you go in the jury room, you’re the ones that can hold them to this. You’re the ones that can make them do the right thing because they haven’t done it on their own and they have no intentions on doing it on their own. You’re going to have to make them do the right thing.

* * * *

Is that doing the right thing? Is that doing the right thing? Well. You know, after we’ve drug him through all this and – [Objection] ... After we’ve gotten through all of this, now all of a sudden it’s, yeah, we’ll agree to that. Is that doing the right thing? Is that taking care of this gentleman?

Kowalski’s counsel also referred to defense counsel as “slick” talkers. He further referred to “corporate greed” when discussing the totaling of damages with the jury:

Finally you’re going to be asked to total up those damages. And that’s going to be a question for you to decide. That’s going to be a question for you to decide. Did they do the right thing or are you going to make them do the right thing? Because I would submit that having a stone fall on someone’s head because you want a pretty elevator and then when he gets seriously hurt to the point he’s retarded, you just kick him out and say we’re giving you nothing. [Objection].

How is that doing the right thing? It’s corporate greed, corporation arrogance. [Objection].

* * * *

Members of the jury, this is up for you to decide. This is now in your hands and I trust that you’ll do the right thing.

In addition, Kowalski’s counsel commented during closing argument that the scene had been tampered with:

You also heard Mr. Salazar tell you somebody rushed in there and tried to clean up the blood. Now you’ve heard a lot of testimony that, well, nobody could have gotten back in time to have cleaned up that blood because he ran to get the camera, but he took this picture right then. Obviously somebody came in there and did something. And you’re going to see the pictures yourself, you’re going to have them in front of you. And you can see in many of the pictures where the blood is smeared in the doorway where somebody came in there and tried to clean it up. Somebody tried to get it up before he could come back with a camera. But they couldn’t get it all, it was too much. You heard Harold tell you it was everywhere. He had to help his friend who was staggering because of this, carry him out, call the EMS, got some towels for him. They did the right thing?

II. STANDARD OF REVIEW

An appellate court reviews a trial court’s denial of a motion for new trial for an abuse of discretion. Brown v. Estate of Stuckey, 749 So. 2d 490, 498 (Fla. 1999); Parisi v. Miranda, 15 So. 3d 816, 817 (Fla. 4th DCA 2009); SDG Dadeland Assocs., Inc. v. Anthony, 979 So. 2d 997, 1001 (Fla. 3d DCA 2008). “A trial court’s discretion regarding counsel’s improper arguments to the jury is guided by whether the comments and arguments were ‘highly prejudicial and inflammatory.’” SDG Dadeland, 979 So. 2d at 1001 (quoting Hagan v. Sun Bank of Mid-Florida, N.A., 666 So. 2d 580, 585 (Fla. 2d DCA 1996), disapproved of on other grounds by Murphy v. Int’l Robotic Sys., Inc., 766 So. 2d 1010, 1013 (Fla.2000)).

The appellants argue that Kowalski’s counsel’s improper comments and arguments were so prejudicial and inflammatory as to deny them a fair trial. Given that the appellants admitted liability prior to trial, we agree with the appellants.

We will address the most egregious statements made by Kowalski’s counsel. Indeed, because liability was admitted, this trial should have been a trial solely on damages. Instead, it became a wide-ranging attack on the appellants unrelated to the calculations of Kowalski’s damages.

III. ANALYSIS

A. Improper Arguments

The law is clear that it is improper for an attorney to disparage an opposing party’s defense of a case or to suggest that a party should be punished for contesting a claim. Carnival Corp. v. Pajares, 972 So. 2d 973 (Fla. 3d DCA 2007). Here, Kowalksi’s counsel did both. Counsel characterized the appellants’ treatment of Kowalski as “kicking him out on the street like a dog,” “kick[ing] him out and say[ing] we’re giving you nothing,” and of having “drug him through all of this.” Counsel repeatedly argued, over objection, that the appellants had refused “to do the right thing” despite knowing “it’s our fault.” Counsel attributed this behavior and the condition of the elevator to the appellants’ “corporate greed and arrogance” because the appellants “wanted a pretty elevator and they didn’t care who got hurt or how bad it was. And then when someone got hurt, they said, you know what, yeah, we made a mistake but we’re not giving you anything.”

In order to rectify the appellants’ “corporate greed and corporate arrogance” and refusal to “do the right thing,” Kowalski’s counsel argued to the jury that it would have to “make them do the right thing because they haven’t done it on their own and they have no intentions on doing it on their own. You’re going to have to make them do the right thing.” In essence, counsel was arguing that the jury had to punish the appellants.1 Kowalski’s counsel’s comments denigrated the appellants’ defense, suggested that they needed to be punished, and served no purpose other than to inflame and prejudice the jury. Such arguments are improper. Pajares, 972 So. 2d at 977; accord State Farm Mut. Auto Ins. Co. v. Revuelta, 901 So. 2d 377, 380 (Fla. 3d DCA 2005).

As noted above, Kowalski’s counsel repeatedly commented, over objection, that the appellants were motivated by “corporate greed and arrogance.” Indeed, Kowalski’s counsel began his opening statement by arguing: “This is a case about a company, 420 Lincoln Road, that wanted to make a couple of extra dollars.” “Corporate greed,” however, was not relevant to any issue in the case; there was no evidence that the appellants installed the granite in the elevator in a way to sacrifice safety in favor of aesthetics. Kowalski’s counsel further contrasted the appellants’ “corporate greed and arrogance” in “want[ing] to put beauty over safety” with Kowalski, who was “just a simple man trying to get by. Not trying to get anything from anybody.” As this Court stated in Pajares, 972 So. 2d at 977, this argument concerning the economic disparity between the parties is “not relevant in determining the issues before the jury, and could only have served to prejudice the members of the jury.” See also Chin v. Caiaffa, 35 Fla. L. Weekly D1742 (Fla. 3d DCA Aug. 4, 2010). Accordingly, as with counsel’s comments denigrating the appellants’ defense, we find these objected-to comments to be inflammatory and prejudicial.

Further, regarding an award of non-economic damages, Kowalski’s counsel suggested that the jury compare Kowalski’s brain to a damaged Picasso painting.

Now, members of the jury, you’ve got to understand that the brain is what separates people from animals. It’s what makes us human. I mean I’m sure you’ve all hear the expression, well, he may be old but he still has his mind or memories are what make us who we are. If that was a Picasso painting that was in the elevator and it got ripped, no one would argue with paying $80 million to replace it. Why is it any different when it’s a man’s brain?

This Court has previously stated that such “value of life” arguments are improper. Chin, 35 Fla. L. Weekly at D1745; Pajares, 972 So. 2d at 979 (improper to compare plaintiff’s life to a Van Gogh painting); Pub. Health Trust of Dade County v. Geter, 613 So. 2d 126, 127 (Fla. 3d DCA 1993) (counsel’s argument that jury should place a monetary value on decedent’s life “just as a monetary value is placed on an eighteen million dollar Boeing 747 or an eight million dollar SCUD missile – was improper, highly inflammatory, and deprived defendant . . . of a fair trial on the issue of damages”). Immediately following counsel’s improper “value of life” argument, Kowalski’s counsel also asked the jury to consider “how much money would you take for me to hit you in the head with a baseball bat as hard as I can?” He concluded his request for non-economic damages by repeatedly referring to Kowalski as “retarded:”

[W]hat’s it worth to go from a normal person to a retarded person for the rest of your life? What’s that worth? . . . [A] man that went from normal, social, making friends to a retarded person now? . . . Because I would submit that having a stone fall on someone’s head because you want a pretty elevator and then when he gets seriously hurt to the point he’s retarded, you just kick him out and say we’re giving you nothing.

Although the appellants did not object to the argument that the jury should compare Kowalski’s brain to a Picasso painting, we find that this constitutes improper argument, when viewed in the overall context of describing Kowalski as “retarded” and asking the jury to consider how much money a reasonable person would accept to be hit in the head with a baseball bat, and we consider it in determining whether the cumulative effect of the objected to comments deprived the appellants of a fair trial.

Finally, Kowalski’s counsel also implied that the appellants had tampered with evidence at the scene of the accident, by stating: And you can see in many of the pictures where the blood is smeared in the doorway where somebody came in there and tried to clean it up. Somebody tried to get it up before he could come back with a camera. But they couldn’t get it all, it was too much. . . .

In essence, Kowalski’s counsel implied that the appellants tried to hide evidence at the scene, based upon nothing other than speculation. There was no evidence presented below that the appellants had tampered with or altered the scene of the accident. Indeed, the condition of the elevator after the accident was not relevant to any issue at trial, as the appellants had already conceded liability. And, although this argument was not objected to below, we note that this sort of argument has been repeatedly condemned by this Court and found to “fall squarely within that category of fundamental error – requiring no preservation below – in which the basic right to a fair and legitimate trial has been fatally compromised.”

Kaas v. Atlas Chem. Co., 623 So. 2d 525, 526 (Fla. 3d DCA 1993). See also SDG Dadeland, 979 So. 2d at 1003 (Fla. 3d DCA 2008) (finding fundamental error in counsel’s comments accusing defense counsel of perpetuating a fraud upon the court by hiding evidence); Johnnides v. Amoco Oil Co., 778 So. 2d 443, 445 (Fla. 3d DCA 2001); George v. Mann, 622 So. 2d 151, 152 (Fla. 3d DCA 1993).

Although “a single improper remark or argument might not be so prejudicial as to require reversal,” Pajares, 972 So. 2d at 979, we find here that the cumulative effect of Kowalksi’s counsel’s numerous improper comments and arguments operated to deprive the appellants of a fair trial. See Muhammad v. Toys “R” Us, Inc., 668 So. 2d 254, 259 (Fla. 1st DCA 1996) (“[T]he collective import of counsel’s personal injections, and irrelevant and inflammatory remarks, was so extensive as to have prejudicially pervaded the entire trial, precluding the jury’s rational consideration of the evidence and resulting in an unfair trial.”).

Accordingly, a new trial is warranted.

B. Insufficient Evidence of Future Medical Expenses

We now turn to the second issue raised on appeal – whether the trial court erred in failing to grant a motion for directed verdict on Kowalski’s claim for future medical expenses. We review a trial court’s ruling on a motion for directed verdict de novo. Diaz v. Impex of Doral, Inc., 7 So. 3d 591, 593 (Fla. 3d DCA 2009). In reviewing a trial court’s denial of a motion for directed verdict, this Court is required to view the evidence in the light most favorable to the nonmoving party. Olsten Health Services, Inc. v. Cody, 979 So. 2d 1221, 1223 (Fla. 3d DCA 2008). “A directed verdict is proper only when the record conclusively shows an absence of facts or inferences from facts to support a jury verdict.” Schreidell v. Shoter, 500 So.2d 228, 232 (Fla. 3d DCA 1986); see also Posner v. Walker, 930 So. 2d 659, 665 (Fla. 3d DCA 2006).

Moreover, concerning an award of future economic damages, such an award is appropriate only “when such damages are established with reasonable certainty.” Auto-Owners Ins. Co. v. Tompkins, 651 So. 2d 89, 91 (Fla. 1995) (emphasis added); accord Loftin v. Wilson, 67 So. 2d 185, 188 (Fla. 1953) (“In every case, plaintiff must afford a basis for a reasonable estimate of the amount of his loss and only medical expenses which are reasonably certain to be incurred in the future are recoverable.”).

It is a plaintiff’s burden to establish that future medical expenses will more probably than not be incurred. Kloster Cruise Ltd. v. Grubbs, 762 So. 2d 552, 556 (Fla. 3d DCA 2000). “That burden may only be met with competent substantial evidence.” Id. There must be “evidence in the record from which the jury could, with reasonable certainty, determine the amount of medical expense [plaintiff] would be likely to incur in the future.” DeAlmeida v. Graham, 524 So. 2d 666, 668 (Fla. 4th DCA 1987). A mere possibility that certain treatment might be obtained in the future cannot form the basis of an award of future medical expenses. Truelove v. Blount, 954 So. 2d 1284, 1288 (Fla. 2d DCA 2007); accord Nevarez v. Friskney, 817 So. 2d 856, 858 (Fla. 5th DCA 2002) (holding that an award for future medical expenses was not supported by the evidence, because even though plaintiff presented expert testimony regarding possible need for future surgery, she presented no evidence regarding the cost of any future surgery and further testified that she would not have the surgery).

Here, the jury awarded Kowalski $120,000 in future medical expenses. Kowalski relies upon the testimony of Dr. Nedd, the medical report of Dr. Rosenkranz, and his own testimony to justify this award.2 Specifically, Dr. Nedd testified that he would strongly recommend that Kowalski obtain neuropsychological testing and a possible evaluation by a psychiatrist. This testimony does not establish with “reasonable certainty” that Kowalski will need this treatment in the future, nor does it provide any basis on which a jury could determine an amount for this treatment. Similarly, a medical report prepared by Dr. Rosenkranz3 stated that Kowalski “will require further care for exacerbations of his symptoms and a cervical MRI is indicated to further assess the extent of joint damage. He additionally should seek psychological counseling.” This testimony does not establish the extent or nature of the “further care” recommended, how often Kowalski would need this treatment in the future, or a basis to determine an amount of expenses. Finally, Kowalski relies upon his own testimony that in the past, he attempted to seek treatment but did not do so because it would have cost between $600 to $750, which he could not afford.4 This testimony, however, presents evidence of past treatment only. It does not establish a need for future treatment, and in no way constitutes evidence of a quantified amount of future medical treatment. As such, it cannot constitute a basis from which a jury could determine an amount of future medical expenses Kowalski would incur.

Accordingly, because there was no competent substantial evidence presented below that Kowalski was reasonably certain to incur future medical expenses or to determine the amount of those expenses, we conclude that the trial court erred in denying the appellants’ motion for directed verdict on this issue. Accordingly, we strike that portion of the jury award.

For the above reasons, we reverse and remand for a new trial solely on the issues of past medical expenses and past and future pain and suffering.5

* * *

See: http://www.3dca.flcourts.org/Opinions/3D09-2299.pdf

Florida Avandia: Dangers with Heart Attacks?

The New York Times is reporting that the credibility of an Avandia memo from GlaxoSmithKline detailing last month’s advisory panel meeting on the controversial diabetes drug is being attacked. A federal official and some members of that same advisory panel have criticized the memo as being misleading, and claim it could even put patients at risk.

As we’ve reported previously, that advisory panel voted 20-12 to recommend that Avandia be allowed to stay on the market. However, 10 panel members voted that its sales should be restricted and that warnings on its label regarding heart risks be strengthened.

Since November 2007, Avandia’s label has included a black box warning – the Food & Drug Administration’s (FDA) strongest safety alert – detailing its association with myocardial ischemia. The black box was added after the Cleveland Clinic published a meta- analysis of 42 clinical trails that showed patients taking Avandia had a 43-percent higher risk of having a heart attack. Since the addition of the black box, evidence linking Avandia to an increased risk of heart attacks has continued to accumulate.

According to the Times, Glaxo sent the memo, dated July 29, at the behest of the FDA. It discussed the TIDE trial, an Avandia study funded by the drug maker. After the advisory panel meeting, the FDA ordered Glaxo to stop enrolling patients in TIDE to give the agency time to study new evidence of Avandia’s risks. Glaxo was also ordered to update physicians and ethics oversight boards involved in the trial regarding all new safety information about the drug, thus the July 29 memo.

Source. 
Enhanced by Zemanta